Trends in LIMS
 | |
| Clinical data | |
|---|---|
| Trade names | Acofide |
| Other names | YM-443, Z-338 |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 84.21–85.95% |
| Metabolism | UGT1A8 and 1A9 (major) |
| Elimination half-life | 10.9–21.7 hours |
| Excretion | Feces (92.7%), urine (5.3%)[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H30N4O5S |
| Molar mass | 450.55 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Acotiamide, sold under the brand name Acofide,[2][3] is a medication manufactured and approved in Japan for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia.[4] It acts as an acetylcholinesterase inhibitor.
References
- ^ "Acofide (acotiamide hydrochloride hydrate) Tablets Review Report" (PDF). Retrieved 29 December 2016.
- ^ Nowlan ML, Scott LJ (August 2013). "Acotiamide: first global approval". Drugs. 73 (12): 1377–83. doi:10.1007/s40265-013-0100-9. PMID 23881665. S2CID 20383853.
- ^ Matsunaga Y, Tanaka T, Saito Y, Kato H, Takei M (February 2014). "[Pharmacological and clinical profile of acotiamide hydrochloride hydrate (Acofide(®) Tablets 100 mg), a novel therapeutic agent for functional dyspepsia (FD)]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 143 (2): 84–94. doi:10.1254/fpj.143.84. PMID 24531902.
- ^ Matsueda K, Hongo M, Tack J, Aoki H, Saito Y, Kato H (June 2010). "Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage". Neurogastroenterology and Motility. 22 (6): 618–e173. doi:10.1111/j.1365-2982.2009.01449.x. PMID 20059698. S2CID 41298446.
